Current treatment options for waldenström macroglobulinemia

Clinical Lymphoma and Myeloma

Volumn 8, Issue 4, 2008, Pages 219-229

  Vijay, Arun ^a   Gertz, Morie A ^b  

^a ALBERT LEA EYE CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Alkylating agents; Lymphoplasmacytic lymphoma; Marrow transplantation; Monoclonal antibodies; Purine nucleoside analogues

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ANTISENSE OLIGONUCLEOTIDE; BORTEZOMIB; CARMUSTINE; CHLORAMBUCIL; CLADRIBINE; CLARITHROMYCIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; IMMUNOGLOBULIN M; LENALIDOMIDE; MELPHALAN; MONOCLONAL ANTIBODY; OBLIMERSEN; PENTOSTATIN; PERIFOSINE; PREDNISONE; PROTEASOME INHIBITOR; PROTEIN KINASE B INHIBITOR; PURINE NUCLEOSIDE DERIVATIVE; RITUXIMAB; SILDENAFIL; THALIDOMIDE; TRICIRIBINE; UNINDEXED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; AMYLOIDOSIS; ANEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; B LYMPHOCYTE; BLADDER CANCER; BLOOD VISCOSITY; BONE MARROW; BONE MARROW CELL; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CELL CYCLE PHASE; CELL INFILTRATION; CHILL; CHROMOSOME BREAKAGE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DNA SYNTHESIS; DRUG DOSE ESCALATION; DRUG EFFICACY; EVENT FREE SURVIVAL; FEVER; FLU LIKE SYNDROME; GENE EXPRESSION; GRANULOCYTOPENIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN BLOOD LEVEL; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MACULOPAPULAR RASH; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; PLASMAPHERESIS; PROTEIN EXPRESSION; RELAPSE; REVIEW; RNA TRANSCRIPTION; SPLENECTOMY; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; VASCULITIS; WALDENSTROEM MACROGLOBULINEMIA; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; WALDENSTROM MACROGLOBULINEMIA;

EID: 60849139137     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2008.n.029     Document Type: Review

References (121)

1. Herrinton LJ, Weiss NS. Incidence of Waldenström's macroglobulinemia. Blood 1993; 82:3148-50.
2. Groves FD, Travis LB, Devesa SS, et al. Waldenström's macroglobulinemia: incidence patterns in the United States, 1988-1994. Cancer 1998; 82:1078-81.
3. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al. Waldenström's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 2000; 18:214-26.
4. Pruzanski W, Shumak KH. Biologic activity of cold-reacting autoantibodies (first of two parts). N Engl J Med 1977; 297:538-42.
5. Owen RG, Barrans SL, Richards SJ, et al. Waldenström macroglobulinemia: development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol 2001; 116:420-8.
6. Owen RG. Developing diagnostic criteria in Waldenström's macroglobulinemia. Semin Oncol 2003; 30:196-200.
7. Vijay A, Gertz MA. Waldenström macroglobulinemia. Blood 2007; 109:5096-103.
8. Treon SP, Gertz MA, Dimopoulos M, et al. Update on treatment recommendations from the Third International Workshop on Waldenström's macroglobulinemia. Blood 2006; 107:3442-6.
9. Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003; 102:3759-64.
10. Alexanian R, Weber D, Delasalle K, et al. Asymptomatic Waldenström's macroglobulinemia. Semin Oncol 2003; 30:206-10.
11. Morra E, Cesana C, Klersy C, et al. Predictive variables for malignant transformation in 452 patients with asymptomatic IgM monoclonal gammopathy. Semin Oncol 2003; 30:172-7.
12. Facon T, Brouillard M, Duhamel A, et al. Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases. J Clin Oncol 1993; 11:1553-8.
13. Kyle RA, Greipp PR, Gertz MA, et al. Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 2000; 108:737-42.
14. Kyrtsonis MC, Vassilakopoulos TP, Angelopoulou MK, et al. Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients: experience from a single hematology unit [published erratum appears in: Ann Hematol 2002; 81:124]. Ann Hematol 2001; 80:722-7.
15. Petrucci MT, Avvisati G, Tribalto M, et al. Waldenström's macroglobulinaemia: results of a combined oral treatment in 34 newly diagnosed patients. J Intern Med 1989; 226:443-7.
16. Case DC Jr, Ervin TJ, Boyd MA, et al. Waldenström's macroglobulinemia: long-term results with the M-2 protocol. Cancer Invest 1991; 9:1-7.
17. Dimopoulos MA, Alexanian R. Waldenström's macroglobulinemia. Blood 1994; 83:1452-9.
18. Annibali O, Petrucci MT, Martini V, et al. Treatment of 72 newly diagnosed Waldenström macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: results and cost analysis. Cancer 2005; 103:582-7.
19. Rodriguez JN, Fernandez-Jurado A, Martino ML, et al. Waldenström's macroglobulinemia complicated with acute myeloid leukemia: report of a case and review of the literature. Haematologica 1998; 83:91-2.
20. USP DI: Vol I: Drug Information for the Health Care Professional. 20th ed. Englewood (CO): Micromedex, Inc.; 2000. Cyclophosphamide; 1155-61.
21. Bouroncle BA, Datta P, Frajola WJ. Waldenström's macroglobulinemia: report of three patients treated with cyclophosphamide. JAMA 1964; 189:729-32.
22. Cass RM, Anderson BR, Vaughan JH. Waldenström's macroglobulinemia with increased serum IgG levels treated with low doses of cyclophosphamide. Ann Intern Med 1969; 71:971-7.
23. Morais MM, Belarmino-Filho JN, Brito GA, et al. Pharmacological and histopathological study of cyclophosphamide-induced hemorrhagic cystitis: comparison of the effects of dexamethasone and Mesna. Braz J Med Biol Res 1999; 32:1211-5.
24. McEvoy GK, editor. AHFS drug information 2006. Bethesda, MD: American Society of Health-System Pharmacists, 2006; 1131-5.
25. Alkeran® [product monograph]. Mississauga (Ontario): GlaxoSmithKline Inc.; June 7, 2006.
26. Bernard J, Seligmann M, Danon F. Attempt at treatment of 21 patients with myeloma or macroglobulinemia with p-di-2-chlorethylamino-1- phenylalanine (melphalan). Nouv Rev Fr Hematol 1962; 2:611-6.
27. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc?RIIIa gene. Blood 2002; 99:754-8.
28. Gluck WL, Hurst D, Yuen A, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 2004; 10:2253-64.
29. Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in Fc?RIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. J Clin Oncol 2005; 23:474-81.
30. Bermudez A, Marco F, Conde E, et al. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 2000; 85:894-5.
31. Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 2000; 96:1184-6.
32. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344:68-9.
33. Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 2001; 345:1000.
34. Westhoff TH, Jochimsen F, Schmittel A, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102:1930.
35. Iyer A, Mathur R, Deepak BV, et al. Fatal adenoviral hepatitis after rituximab therapy. Arch Pathol Lab Med 2006; 130:1557-60.
36. Gertz MA, Rue M, Blood E, et al. Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004;45:2047-55.
37. Byrd JC, White CA, Link B, et al. Rituximab therapy in Waldenström's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol 1999; 10:1525-7.
38. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma [published erratum appears in: J Clin Oncol 2000;18:2006]. J Clin Oncol 2000; 18:317-24.
39. Treon SP, Agus DB, Link B, et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenström's macroglobulinemia. J Immunother 2001; 24:272-9.
40. Dimopoulos MA, Zervas C, Zomas A, et al. Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia. Clin Lymphoma 2002; 3:163-6.
41. Treon SP, Emmanouilides C, Kimby E, et al. Waldenström's Macroglobulinemia Clinical Trials Group. Extended rituximab therapy in Waldenström's macroglobulinemia. Ann Oncol 2005; 16:132-8.
42. Dimopoulos MA, Alexanian R, Gika D, et al. Treatment of Waldenström's macroglobulinemia with rituximab: prognostic factors for response and progression. Leuk Lymphoma 2004; 45:2057-61.
43. Hunter ZR, Boxer M, Kahl B, et al, on behalf of the WMCTG. Phase II study of alemtuzumab in lymphoplasmacytic lymphoma: results of WMCTG trial 02-079. J Clin Oncol 2006; 24(16 suppl):427s (Abstract 7523).
44. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenström's macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007; 25:3344-9.
45. Treon SP, Hunter Z, Branagan AR. CHOP plus rituximab therapy in Waldenström's macroglobulinemia. Clin Lymphoma 2005; 5:273-7.
46. Branagan A, Hunter Z, Santos DD, et al. Thalidomide and rituximab in Waldenström's macroglobulinemia. Blood 2004; 104:415a (Abstract 1484).
47. Gertz MA, Anagnostopoulos A, Anderson K, et al. Treatment recommendations in Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Semin Oncol 2003; 30:121-6.
48. Renaud S, Fuhr P, Gregor M, et al. High-dose rituximab and anti-MAG-associated polyneuropathy. Neurology 2006; 66:742-4.
49. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101:3827-34.
50. Ghobrial IM, Uslan DZ, Call TG, et al. Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenström macroglobulinemia does not indicate failure of response. Am J Hematol 2004; 77:329-30.
51. Treon SP, Branagan AR, Hunter Z, et al. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenström's macroglobulinemia. Ann Oncol 2004; 15:1481-3.
52. Ghobrial IM, Fonseca R, Greipp PR, et al. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenström macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer 2004; 101:2593-8.
53. Aslan DL, Peterson BA, Long-Tsai M, et al. Early-onset autoimmune hemolytic anemia after cladribine therapy for Waldenström's macroglobulinemia. Transfusion 2006; 46:90-4.
54. Dimopoulos MA, Weber D, Delasalle KB, et al. Treatment of Waldenström's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. Ann Oncol 1995; 6:49-52.
55. Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood 2001; 98:41-8.
56. Weber DM, Dimopoulos MA, Delasalle K, et al. 2- Chlorodeoxyadenosine alone and in combination for previously untreated Waldenström's macroglobulinemia. Semin Oncol 2003; 30:243-7.
57. Leblond V, Levy V, Maloisel F, et al. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin- prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease. Blood 2001; 98:2640-4.
58. Tam CS, Wolf MM, Westerman D, et al. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia. Clin Lymphoma Myeloma 2005; 6:136-9.
59. Tamburini J, Levy V, Chaleteix C, et al. Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients. Leukemia 2005; 19:1831-4.
60. Hensel M, Villalobos M, Kornacker M, et al. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma. Clin Lymphoma Myeloma 2005; 6:131-5.
61. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992; 340:952-6.
62. Dimopoulos MA, Weber DM, Kantarjian H, et al. 2Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine. Ann Oncol 1994; 5:288-9.
63. Fridrik MA, Jäger G, Baldinger C, et al. Arbeitsgemeinschaft Medikamentose Tumortherapie. First-line treatment of Waldenström's disease with cladribine. Ann Hematol 1997; 74:7-10.
64. Delannoy A, Van Den Neste E, Michaux JL, et al. Cladribine for Waldenström's macroglobulinaemia. Br J Haematol 1999; 104:933-4.
65. Bryson HM, Sorkin EM. Cladribine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies. Drugs 1993; 46:872-94.
66. Ling S, Joshua DE, Gibson J, et al. Transformation and progression of Waldenström's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation? Am J Hematol 2006;81:110-4.
67. Adkins JC, Peters DH, Markham A. Fludarabine: an update of its pharmacology and use in the treatment of haematological malignancies. Drugs 1997; 53:1005-37.
68. Dimopoulos MA, O'Brien S, Kantarjian H, et al. Fludarabine therapy in Waldenström's macroglobulinemia. Am J Med 1993; 95:49-52.
69. Foran JM, Rohatiner AZ, Coiffier B, et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 1999; 17:546-53.
70. Thalhammer-Scherrer R, Geissler K, Schwarzinger I, et al. Fludarabine therapy in Waldenström's macroglobulinemia. Ann Hematol 2000; 79:556-9.
71. Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in Waldenström's macroglobulinemia: an update of a US intergroup trial (SWOG S9003). Semin Oncol 2003; 30:220-5.
72. Ho AD, Hensel M. Pentostatin for the treatment of indolent lymphoproliferative disorders. Semin Hematol 2006; 43(suppl 2):S2-S10.
73. Laszlo D, Andreola G, Rabascio C, et al. Cladribine (2-CDA) and rituximab combination treatment for patients with Waldenström's macroglobulinemia (WM) or small lymphocytic lymphoma (SLL): clinical preliminary reports of a multicenter study. Presented at: the 4th International Workshop on Waldenström's Macroglobulinemia; June 25-30, 2007; Kos, Greece.
74. Tedeschi A, Miqueleiz AS, Ricci F, et al. Fludarabine, cyclophosphamide and rituximab an effective regimen characterized by high incidence of delayed responses in Waldenström's macroglobulinemia. Haematologica 2007; 92(suppl 2):227.
75. Dimopoulos MA, Hamilos G, Efstathiou E, et al. Treatment of Waldenström's macroglobulinemia with the combination of fludarabine and cyclophosphamide. Leuk Lymphoma 2003; 44:993-6.
76. Chen CI, Kouroukis T, White D, et al. Bortezomib is active in Waldenström's macroglobulinemia (WM): results of a National Cancer Institute of Canada (NCIC) phase II study in previously untreated or treated WM. J Clin Oncol 2006; 24(16 suppl):432s (Abstract 7543).
77. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib. Haematologica 2005; 90:1655-8.
78. Treon SP, Soumerai JD, Patterson CJ, et al. Bortezomib, dexamethasone and rituximab (BDR) is a highly active regimen in the primary therapy of Waldenström's macroglobulinemia: planned interim results of WMCTG clinical trial 05-180. Blood 2006; 108:783a (Abstract 2765).
79. Jia X, Leleu X, Moreau A-S, et al. The proteasome inhibitor NPI-0052 in combination with bortezomib induces antitumor activity in Waldenström macroglobulinemia. Presented at: the 4th International Workshop on Waldenström's Macroglobulinemia; June 25-30, 2007; Kos, Greece.
80. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4:314-22.
81. Settles B, Stevenson A, Wilson K, et al. Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide. Cell Mol Biol (Noisy-le-grand) 2001; 47:1105-14.
82. Zeldis JB, Schafer PH, Bennett BL, et al. Potential new therapeutics for Waldenström's macroglobulinemia. Semin Oncol 2003; 30:275-81.
83. Fujita J, Mestre JR, Zeldis JB, et al. Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin Cancer Res 2001; 7:3349-55.
84. Crane E, List A. Lenalidomide: an immunomodulatory drug. Future Oncol 2005; 1:575-83.
85. Cavaletti G, Beronio A, Reni L, et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology 2004; 62:2291-3.
86. Dimopoulos MA, Tsatalas C, Zomas A, et al. Treatment of Waldenström's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Semin Oncol 2003; 30:265-9.
87. Coleman M, Leonard J, Lyons L, et al. Treatment of Waldenström's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Semin Oncol 2003; 30:270-4.
88. Bartlett JB, Michael A, Clarke IA, et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 2004; 90:955-61.
89. Soumerai J, Branagan A, Hunter Z, et al. Use of immunomodulators thalidomide and lenalidomide to augment rituximab clinical activity in Waldenström's macroglobulinemia. Presented at: 4th International Workshop on Waldenström's Macroglobulinemia; June 25 to 30, 2007; Kos, Greece.
90. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998; 10:262-7.
91. Leleu X, Ngo H, Runnels J, et al. The PI3K/Akt pathway is an important regulator of homing and adhesion in Waldenström's macroglobulinemia. Blood 2006; 108:684a (Abstract 2417).
92. Kondapaka SB, Singh SS, Dasmahapatra GP, et al. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003; 2:1093-103.
93. Ghobrial IM, Leleu X, Treon SP, et al. Phase II trial of perifosine (KRX-0401) in relapsed and/or refractory Waldenström's macroglobulinemia: preliminary results. Presented at: 4th International Workshop on Waldenström's Macroglobulinemia; June 25 to 30, 2007; Kos, Greece.
94. Leleu X, O'Sullivan G, Jia X, et al. Novel agent perifosine enhances antitumor activity of bortezomib, rituximab and other conventional therapies in Waldenström's macroglobulinemia. Blood 2006; 108:712a (Abstract 2517).
95. Moreau A-S, Jia X, O'Sullivan G, et al. The selective protein kinase CB inhibitor, enzastaurin, induces in vitro and in vivo antitumor activity in Waldenström's macroglobulinemia. Blood 2006; 108:707a (Abstract 2496).
96. Wotring LL, Townsend LB, Jones LM, et al. Dual mechanisms of inhibition of DNA synthesis by triciribine. Cancer Res 1990; 50:4891-9.
97. Yang L, Dan HC, Sun M, et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 2004; 64:4394-9.
98. Jane SM, Salem HH. Treatment of resistant Waldenström's macro-globulinemia with high dose glucocorticosteroids. Aust N Z J Med 1988; 18:77-8.
99. O'Reilly RA, MacKenzie MR. Primary macrocryogelglobulinemia: remission with adrenal corticosteroid therapy. Arch Intern Med 1967; 120:234-8.
100. Tamm I, Dörken B, Hartmann G. Antisense therapy in oncology: new hope for an old idea? Lancet 2001; 358:489-97.
101. Gertz MA, Geyer SM, Badros A, et al. Early results of a phase I trial of oblimersen sodium for relapsed or refractory Waldenström's macroglobulinemia. Clin Lymphoma 2005; 5:282-4.
102. Treon SP, Tournilhac O, Branagan AR, et al. Clinical responses to sildenafil in Waldenström's macroglobulinemia. Clin Lymphoma 2004; 5:205-7.
103. Patterson CJ, Soumerai J, Hunter Z, et al. Sildenafil citrate suppresses disease progression in patients with Waldenström's macroglobulinemia. J Clin Oncol 2006; 24(16 suppl):435s (Abstract 7556).
104. Anagnostopoulos A, Giralt S. Stem cell transplantation (SCT) for Waldenström's macroglobulinemia (WM). Bone Marrow Transplant 2002; 29:943-7.
105. Munshi NC, Barlogie B. Role for high-dose therapy with autologous hematopoietic stem cell support in Waldenström's macroglobulinemia. Semin Oncol 2003; 30:282-5.
106. Anagnostopoulos A, Hari PN, Perez WS, et al. Autologous or allogeneic stem cell transplantation in patients with Waldenström's macroglobulinemia. Biol Blood Marrow Transplant 2006; 12:845-54.
107. Tournilhac O, Leblond V, Tabrizi R, et al. Transplantation in Waldenström's macroglobulinemia--the French experience. Semin Oncol 2003; 30:291-6.
108. Visani G, Lemoli RM, Tosi P, et al. Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. Br J Haematol 1999; 105:775-9.
109. Anderson LD Jr, Sandmaier BM, Maris MB, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) for refractory Waldenström's macroglobulinemia (WM). Blood 2006; 108:862a (Abstract 3034).
110. Clark WF, Rock GA, Buskard N, et al. Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Intern Med 1999; 131:453-62.
111. Humphrey JS, Conley CL. Durable complete remission of macroglobulinemia after splenectomy: a report of two cases and review of the literature. Am J Hematol 1995; 48:262-6.
112. Jacobs P, Wood L, le Roux I, et al. Waldenström macroglobulinaemia treated with sequential hemibody irradiation. J Clin Apher 1987; 3:181-4.
113. Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003; 101:3413-5.
114. Nabhan C, Patton D, Gordon LI, et al. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma 2004; 45:2269-73.
115. Hatjiharissi E, Ho AW, Xu L, et al. Preclinical in vitro and in vivo evidence support a therapeutic role for the CD70 directed monoclonal antibody (SGN-70) in Waldenström's macroglobulinemia (WM). Blood 2006; 108:705a (Abstract 2490).
116. Ho AW, Hatjiharissi E, Branagan A, et al. Therapeutic targeting of CD70 and CD27-CD70 interactions with the monoclonal antibody SGN-70 in Waldenström's macroglobulinemia (WM). J Clin Oncol 2006; 24(16 suppl):102s (Abstract 2509).
117. Rossi J-F, Moreaux J, Rose M, et al. A phase I/II study of atacicept (TACI-Ig) to neutralize APRIL and BLyS in patients with refractory or relapsed multiple myeloma (MM) or active previously treated Waldenström's macroglobulinemia (WM). Blood 2006; 108:1022a (Abstract 3578).
118. Tournilhac O, Santos DD, Xu L, et al. Mast cells in Waldenström's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol 2006; 17:1275-82.
119. Treon SP, Soumerai JD, Patterson CJ, et al. Imatinib mesylate (Gleevec®) is active in relapsed/refractory Waldenström's macroglobulinemia: planned interim results of WMCTG clinical trial 05-140. Blood 2006; 108:704a (Abstract 2484).
120. Moreau A-S, Jia X, Leleu X, et al. Simvastatin, an HMG-CoA inhibitor, induces in vitro antitumor activity in Waldenström's macroglobulinemia. Presented at: 4th International Workshop on Waldenström's Macroglobulinemia; June 25-30, 2007; Kos, Greece.
121. Roccaro AM, Leleu X, Moreau A-S, et al. Resveratrol exerts antiproliferative effect and induces apoptosis in Waldenström's macroglobulinemia. Presented at: 4th International Workshop on Waldenström's Macroglobulinemia; June 25-30, 2007; Kos, Greece.